US Patent Issued to Hexamer Therapeutics on June 9 for "Immunotherapeutic for prostate cancer treatment" (Idaho Inventors)

ALEXANDRIA, Va., June 9 -- United States Patent no. 12,648,985, issued on June 9, was assigned to Hexamer Therapeutics Inc. (Pullman, Wash.).

"Immunotherapeutic for prostate cancer treatment" was invented by Keith Douglas Miller (Moscow, Idaho) and Robert Bogden (Viola, Idaho).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure describes a GnRH therapeutic for neutralizing GnRH levels in subjects which can reduce testosterone levels to attenuate or eliminate prostate cancer cell growth and/or metastasis. The therapeutic is produced synthetically. The GnRH therapeutic includes a hapten carrier (hC) comprising a monomeric peptide (MP), synthesized separately from the GnRH peptide, and followin...